@article{MTMT:34824081,
	title = {Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches},
	url = {https://m2.mtmt.hu/api/publication/34824081},
	author = {Molnár, Tihamér and Lehoczki, Andrea Marianna and Fekete, Mónika and Várnai, Réka and Zavori, Laszlo and Erdő-Bonyár, Szabina and Simon, Diána and Berki, Tímea and Csécsei, Péter and Ezer, Erzsébet},
	doi = {10.1007/s11357-024-01165-5},
	journal-iso = {GEROSCIENCE},
	journal = {GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE)},
	volume = {In press},
	unique-id = {34824081},
	issn = {2509-2715},
	abstract = {The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has introduced the medical community to the phenomenon of long COVID, a condition characterized by persistent symptoms following the resolution of the acute phase of infection. Among the myriad of symptoms reported by long COVID sufferers, chronic fatigue, cognitive disturbances, and exercise intolerance are predominant, suggesting systemic alterations beyond the initial viral pathology. Emerging evidence has pointed to mitochondrial dysfunction as a potential underpinning mechanism contributing to the persistence and diversity of long COVID symptoms. This review aims to synthesize current findings related to mitochondrial dysfunction in long COVID, exploring its implications for cellular energy deficits, oxidative stress, immune dysregulation, metabolic disturbances, and endothelial dysfunction. Through a comprehensive analysis of the literature, we highlight the significance of mitochondrial health in the pathophysiology of long COVID, drawing parallels with similar clinical syndromes linked to post-infectious states in other diseases where mitochondrial impairment has been implicated. We discuss potential therapeutic strategies targeting mitochondrial function, including pharmacological interventions, lifestyle modifications, exercise, and dietary approaches, and emphasize the need for further research and collaborative efforts to advance our understanding and management of long COVID. This review underscores the critical role of mitochondrial dysfunction in long COVID and calls for a multidisciplinary approach to address the gaps in our knowledge and treatment options for those affected by this condition.},
	year = {2024},
	eissn = {2509-2723},
	orcid-numbers = {Fekete, Mónika/0000-0001-8632-2120; Berki, Tímea/0000-0002-0134-8127}
}

@article{MTMT:34476390,
	title = {A second update on mapping the human genetic architecture of COVID-19.},
	url = {https://m2.mtmt.hu/api/publication/34476390},
	doi = {10.1038/s41586-023-06355-3},
	journal-iso = {NATURE},
	journal = {NATURE},
	volume = {621},
	unique-id = {34476390},
	issn = {0028-0836},
	year = {2023},
	eissn = {1476-4687},
	pages = {E7-E26}
}

@article{MTMT:34202983,
	title = {Acute Phase Protein Orosomucoid (Alpha-1-Acid Glycoprotein) Predicts Delayed Cerebral Ischemia and 3-Month Unfavorable Outcome after Aneurysmal Subarachnoid Hemorrhage},
	url = {https://m2.mtmt.hu/api/publication/34202983},
	author = {Závori, László and Várnai, Réka and Molnár, Tihamér and Szirmay, Balázs and Borbásné Farkas, Kornélia and Schwarcz, Attila and Csécsei, Péter},
	doi = {10.3390/ijms242015267},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {34202983},
	issn = {1661-6596},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Závori, László/0000-0002-1715-4167; Borbásné Farkas, Kornélia/0000-0002-5349-6527}
}

@misc{MTMT:34102938,
	title = {A second update on mapping the human genetic architecture of COVID-19},
	url = {https://m2.mtmt.hu/api/publication/34102938},
	author = {Andrea, Ganna},
	unique-id = {34102938},
	year = {2023}
}

@article{MTMT:34043095,
	title = {Different Kinetics of Serum ADAMTS13, GDF-15, and Neutrophil Gelatinase-Associated Lipocalin in the Early Phase of Aneurysmal Subarachnoid Hemorrhage},
	url = {https://m2.mtmt.hu/api/publication/34043095},
	author = {Csécsei, Péter and Oláh, Csaba Zsolt and Várnai, Réka and Simon, Diána and Erdő-Bonyár, Szabina and Berki, Tímea and Czabajszki, Mate and Závori, László and Schwarcz, Attila and Molnár, Tihamér},
	doi = {10.3390/ijms241311005},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {34043095},
	issn = {1661-6596},
	abstract = {Growth differentiation factor 15 (GDF-15), neutrophil gelatinase-associated lipocalin (NGAL), and ADAMTS13 have previously been implicated in the pathophysiological processes of SAH. In the present study, we aim to examine their role in the early period of SAH and their relationship to primary and secondary outcomes. Serum samples were collected at five time periods after SAH (at 24 h (D1), at 72 h (D3), at 120 h (D5), at 168 h (D7) and at 216 h (D9), post-admission) and) were measured by using MILLIPLEX Map Human Cardiovascular Disease (CVD) Magnetic Bead Panel 2. We included 150 patients with SAH and 30 healthy controls. GDF-15 levels at D1 to D9 were significantly associated with a 3-month unfavorable outcome. Based on the ROC analysis, in patients with a good clinical grade at admission (WFNS I-III), the GDF-15 value measured at time point D3 predicted a 3-month unfavorable outcome (cut-off value: 3.97 ng/mL, AUC:0.833, 95%CI: 0.728–0.938, sensitivity:73.7%, specificity:82.6%, p < 0.001). Univariate binary logistic regression analysis showed that serum NGAL levels at D1-D5 and ADAMTS13 levels at D7-D9 were associated with MVS following SAH. GDF-15 is an early indicator of a poor 3-month functional outcome even in patients with mild clinical conditions at admission.},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Berki, Tímea/0000-0002-0134-8127; Závori, László/0000-0002-1715-4167}
}

@article{MTMT:33647476,
	title = {Cystatin-c May Indicate Subclinical Renal Involvement, While Orosomucoid Is Associated with Fatigue in Patients with Long-COVID Syndrome},
	url = {https://m2.mtmt.hu/api/publication/33647476},
	author = {Zavori, Laszlo and Molnár, Tihamér and Várnai, Réka and Kanizsai, Andrea and Nagy, Lajos and Vadkerti, Bence and Szirmay, Balázs and Schwarcz, Attila and Csécsei, Péter},
	doi = {10.3390/jpm13020371},
	journal-iso = {J PERS MED},
	journal = {JOURNAL OF PERSONALIZED MEDICINE},
	volume = {13},
	unique-id = {33647476},
	keywords = {fatigue; Orosomucoid; L-arginine; renal function; CYSTATIN-C; Symmetric dimethylarginine; long-COVID syndrome},
	year = {2023},
	eissn = {2075-4426}
}

@article{MTMT:33567482,
	title = {Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme},
	url = {https://m2.mtmt.hu/api/publication/33567482},
	author = {Kanizsai, Andrea and Zavori, Laszlo and Molnár, Tihamér and Tőkés-Füzesi, Margit and Szalai, Zoltan and Berecz, Janos and Várnai, Réka and Péterfi, Zoltán and Schwarcz, Attila and Csécsei, Péter},
	doi = {10.3390/vaccines11010182},
	journal-iso = {VACCINES-BASEL},
	journal = {VACCINES (BASEL)},
	volume = {11},
	unique-id = {33567482},
	abstract = {Background: It is known that adverse reactions following SARS-CoV-2 vaccinations show a positive correlation with the subsequent antibody titer. However, it is not clear how the adverse reactions following the booster vaccination are related to the antibody levels that can be measured after a 3rd dose. The primary goal of this study was to investigate whether the adverse reactions following the booster vaccination show a correlation with subsequent antibody levels. Methods: Adverse reactions occurring within 7 days after the 3rd vaccination were recorded and the anti-SARS-CoV-2 spike protein immunoglobulin (Ig) level in the venous blood was measured on post-vaccination 14th, 60th and 120th days. Results: A total of 218 volunteers were included in the study. Main findings: (i) The adverse reactions that appeared after the booster dose did not show a positive correlation with the subsequent antibody level, except a correlation in the case of fever; (ii) there were more symptomatic patients in the group receiving heterologous booster vaccine, (iii) fever after the 2nd dose was independently associated with a reduction in the likelihood of COVID-19 positivity after the booster dose. Conclusion: No adverse reactions, but fever showed a correlation with the antibody level after the booster SARS-CoV-2 vaccine.},
	year = {2023},
	eissn = {2076-393X},
	orcid-numbers = {Zavori, Laszlo/0000-0002-1715-4167; Péterfi, Zoltán/0000-0001-9658-153X}
}

@misc{MTMT:33652631,
	title = {A SÚLYOS FÁRADTSÁG ÉS MEMÓRIAZAVAR ÖSSZEFÜGG A SARS-COV-2-ELLENES ANTITESTEK ALACSONYABB SZÉRUMSZINTJÉVEL LONG-COVID BETEGEKBEN},
	url = {https://m2.mtmt.hu/api/publication/33652631},
	author = {Várnai, Réka},
	unique-id = {33652631},
	year = {2022}
}

@misc{MTMT:33652627,
	title = {A SÚLYOS FÁRADTSÁG ÉS MEMÓRIAZAVAR ÖSSZEFÜGG A SARS-COV-2-ELLENES ANTITESTEK ALACSONYABB SZÉRUMSZINTJÉVEL LONG-COVID BETEGEKBEN},
	url = {https://m2.mtmt.hu/api/publication/33652627},
	author = {Várnai, Réka},
	unique-id = {33652627},
	year = {2022}
}

@misc{MTMT:33652613,
	title = {A SÚLYOS FÁRADTSÁG ÉS MEMÓRIAZAVAR ÖSSZEFÜGG A SARS-COV-2-ELLENES ANTITESTEK ALACSONYABB SZÉRUMSZINTJÉVEL LONG-COVID BETEGEKBEN},
	url = {https://m2.mtmt.hu/api/publication/33652613},
	author = {Várnai, Réka},
	unique-id = {33652613},
	year = {2022}
}